United States: Patent Eligibility In The Life Sciences: Supreme Court Declines Review Of Ariosa Diagnostics v. Sequenom

On June 27, 2016, the U.S. Supreme Court denied certiorari in Ariosa Diagnostics, Inc. v. Sequenom, Inc.,1 thereby letting stand the Federal Circuit's June 2015 ruling that Sequenom's diagnostic test for prenatal DNA is not patent eligible. In Ariosa, the Federal Circuit found that the claims, which were recognized to be directed to a groundbreaking discovery, are not entitled to patent protection because the presence of prenatal DNA in a maternal sample is a natural phenomenon.

The decision to decline review of patent eligible subject matter in the diagnostic and life science areas may reinforce the courts' increased scrutiny of life science claims after recent Supreme Court decisions including Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012).

As a result, this decision represents a welcomed victory for defendants seeking to challenge method claims asserted against them as being patent ineligible. For companies seeking patent claims to diagnostic methods, biomarker detection, and other life science-based technologies, however, the decision may lead to continuing uncertainties regarding the validity or patentability of numerous patents or applications in this area. While this uncertainty may be concerning to these companies, dicta by the Supreme Court in its Mayo decision and recent guidelines issued by the United States Patent and Trademark Office (USPTO)2 offer some hope that certain subject matter may remain patent eligible in this area.


Subject matter eligibility is governed by 35 U.S.C. §101 and extends patent protection to "any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof." There are, however, judicially created exceptions, including laws of nature, natural phenomena, or abstract ideas, which are not eligible for patent protection.3 Nonetheless, the bar for patent eligibility has, historically, been relatively low. That is, until the past few years.

The scope of what constitutes patent ineligible subject matter has increased following the Supreme Court's decision in Mayo, which held that a method of correlating effectiveness of treatment to a natural metabolite of an administered drug is a law of nature, and, therefore, not patent eligible.

Mayo provided a two-part framework for determining whether an invention is patent eligible subject matter.4 The framework first assesses the claims to determine if they are directed to a patent ineligible concept (i.e., a law of nature, natural phenomena, or abstract idea). If they are, then the claims are not patent eligible unless the claim as a whole is directed to "significantly more" than the law of nature, natural phenomena, or abstract idea itself.

As technologies are now being evaluated, or reevaluated, in the post-Mayo world, a new question arises: "Is this still patent eligible subject matter under the Mayo framework?" Some claims that would have been patent eligible just a few years ago may no longer be eligible for patent protection today in view of the more stringent standards for patent eligibility in Mayo and other court decisions.


Sequenom was granted a patent to a method of non-invasively measuring cell-free fetal DNA (cffDNA) in maternal plasma and serum. The inventors discovered that cffDNA, which originated with the fetus but circulates freely in mother's bloodstream, could be isolated, amplified, and detected as an alternative to the more invasive prenatal diagnostic techniques.5 After being sued for infringement by Sequenom, Ariosa challenged the patent as being invalid for being directed to a patent ineligible natural phenomenon.

The district court applied the Mayo two-part test and concluded that the diagnostic methods were patent ineligible, since the claims were directed to a natural phenomenon, the cffDNA, and the remaining steps were "well-understood, routine, and conventional" in the field.

On appeal to the Federal Circuit, Sequenom argued that "the claimed methods are patent eligible applications of a natural phenomenon, specifically a method for detecting paternally inherited cffDNA."6 In support of patent eligibility, Sequenom argued that "before the '540 patent, no one was using the plasma or serum of pregnant mothers to amplify and detect paternally-inherited cffDNA."7 Nonetheless, the Federal Circuit reasoned that, in view of the "sweeping language"8 of Mayo, it was obligated to affirm the district court's ruling that the claimed methods were not eligible for patent protection.9 Under the guidelines of Mayo, the court found that the cffDNA constituted a "natural phenomenon" (Mayo step 1) and the remaining steps of amplifying and detecting the cffDNA were "well-understood, routine, and conventional activity" (Mayo step 2).10

The court held that "[w]here claims of a method patent are directed to an application that starts and ends with a naturally occurring phenomenon, the patent fails to disclose patent eligible subject matter if the methods themselves are conventional, routine and well understood applications in the art."11

Judge Linn authored a concurring opinion that evinced the reluctance of at least some judges of the Federal Circuit to invalidate Sequenom's claims as being patent ineligible. Judge Linn noted, "[t]his case represents the consequence—perhaps unintended—of that broad language [in Mayo] in excluding a meritorious invention from the patent protection it deserves and should have been entitled to retain."12 This criticism of the potential reach of the Mayo decision offered hope that the issue was ripe for review by the Supreme Court. Unfortunately, by declining certiorari, the Supreme Court may be reinforcing the broad-sweeping impact of the Mayo framework.


Because the Supreme Court has declined to review the issue of patent eligibility at this time, the Mayo framework will likely be the test for patent eligibility for the foreseeable future. So far, courts have provided little guidance in the life sciences arena as to what additional elements must be present for a claim to be directed to "significantly more" than the judicial exception. Nevertheless, there is no categorical exclusion of subject matter eligibility in this area, since even the Supreme Court in Mayo stated that "too broad an interpretation of this exclusionary principle could eviscerate patent law"13 and that "an application of a law of nature...to a known structure or process may well be deserving of patent protection."14

Without further guidance from the Supreme Court, the lower courts will likely continue to invalidate certain patent claims. For example, on April 8, 2016, the Federal Circuit in Genetic Techs. Ltd. v. Merial L.L.C., 818 F.3d 1369 (Fed. Cir. 2016) struck down claims directed to "methods of detecting a coding region allele by amplifying and analyzing any linked non-coding region" for failing to satisfy patent eligibility under Mayo. As in Ariosa, the court concluded that the exception at issue (here, a "law of nature") was applied using only the conventional and routine steps of amplifying and detecting the DNA.


The impact that the Supreme Court's denial of certiorari in Ariosa will have is unclear. While the Court decided not to revisit the Mayo framework at this time, it does not foreclose the possibility that the Court will revisit it in the future. Nonetheless, it appears that, at least for now, the lower courts will continue to invalidate life sciences-related method claims. If the Court does not take up this issue in the future, the current test for patent eligibility under Mayo will remain the law unless Congress steps in—An event that seems unlikely to occur soon.

In the meantime, clients pursuing intellectual property protection for certain method claims in the life sciences will want to work closely with their patent counsel to address the impact of these recent decisions on their businesses and patent estates, while defendants in cases may want to consider how these cases might apply to claims asserted against them.


1 788 F.3d 1371 (Fed. Cir. 2015).

2 May 2016 Subject Matter Eligibility Update, 88 Fed. Reg. 27381 (May 6, 2016).

3 See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 4 Mayo, 132 S. Ct. at 1293–94.

4 Mayo, 132 S. Ct. at 1293–94.

5 Id.

6 Ariosa Diagnostics, Inc. v. Sequenom, Inc., Nos. 2014-1139, 2014-1144, slip op. at *11 (Fed. Cir. 2015) (emphasis added).

7 Id. at *15 (citing Appellants' Br. 49).

8 Id. at *4 (Linn, J., concurring).

9 Id. at *16 (majority).

10 Id. at *13.

11 Id. 12 Id. at *2 (Linn, J., concurring).

12 Id. at *2 (Linn, J., concurring).

13 Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289, 1293 (2012).

14 Id. at 1293-94 (quoting Diamond v. Diehr, 450 U.S. 175, 187 (1981)).

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Karen G. Potter
James J. Mullen III, Ph.D.
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.